Superfluid Dx, a San Francisco, CA-based company which specializes in advancing solutions for the diagnosis of the Alzheimer’s disease, raised an undisclosed amount in Series A funding.
The round was led by WRQ Sciences. Alzheimer’s Drug Discovery Foundation’s (ADDF) Diagnostics Accelerator (DxA) also participated.
The company intends to use the funds to expand operations and its R&D sector.
Led by Gajus Worthington, CEO, Superfluid Dx is a company which specializes in diagnosis for Alzheimer’s disease. It is building a translational science and data analysis platform to leverage cell-free mRNA to diagnose neruo-degenerative and other diseases. Its proprietary science and data analysis platform enables the diagnostic accessibility of cf-mRNA which is a fundamental signal for all cellular activity.
Commentino on the news, Gajus Worthington said: “Existing tests for Alzheimer’s Disease and related dementias can miss up to 30% of patients developing the disease and misdiagnose another third. The breakthrough work at Superfluid Diagnostics will transform the Alzheimer’s Disease diagnostic landscape.“
FinSMEs
21/12/2023